Drug Discovery World

APRIL 18, 2023

A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in paediatric patients with solid tumours exhibiting DNA replication stress and/or DNA repair deficiencies, according to new data.

DNA 52

DNA Genome Genomics HR 52

Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 101

FDA Approval Drugs Sales Development 101

Drug Discovery World

FEBRUARY 21, 2023

The FDA has granted expanded approval for Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for patients with HR-positive/HER2-negative metastatic breast cancer who have received hormonal therapy and at least two additional therapies in the metastatic setting. GlobalData’s forecasts project sales to reach 2.8

HR 52

HR Hormones Sales Antibody 52

Drug Discovery World

OCTOBER 7, 2022

HR : We have some great assets at CRUK – access to world-leading cancer biology, strong, proven drug discovery capabilities and access to a network of life-science organisations – Cancer Research Horizons was set up to expand on these assets and make them accessible to researchers, investors and industry through collaboration. Hamish Ryder.

HR 52

HR Research Drugs Development 52

XTalks

FEBRUARY 5, 2024

It represents the inaugural targeted therapy designed to impede the DNA damage response (DDR) in cells or tumors exhibiting a deficiency in homologous recombination repair (HRR), notably those with mutations in BRCA1 and/or BRCA2 or those where deficiency is induced by other agents, such as DNA-damaging chemotherapies.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

MARCH 16, 2022

In the key secondary endpoint of OS, LYNPARZA reduced the risk of death by 32% (HR=0.68 [98.5% LYNPARZA is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells. 0.97]; p=0.009) versus placebo.

Trials 52

Trials DNA Clinical Trials Clinical Trials 52

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Marketing 75

Marketing Production Drugs Licensing 75

pharmaphorum

OCTOBER 6, 2020

And make sure your HR, training and communications teams are looped in, informed and armed with the right information and tools to encourage and support adoption. You should drive home the notion of ‘one company’ and keep an eagle-eye out for cowboys building their own rogue programmes.

Regulation 114

Regulation Life Science Production HR 114

The Pharma Data

DECEMBER 21, 2020

Adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% in the primary endpoint of DFS in patients with Stage II and IIIA disease (hazard ratio [HR] 0.17; 95% confidence interval [CI] 0.12-0.23; 0.23; p<0.0001). 0.27; p<0.0001).

Trials 52

Trials Medicine HR Development 52

Pfizer

DECEMBER 20, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets).

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

SEPTEMBER 2, 2021

Changing treatment paradigms with industry-leading PARP inhibitors and next-wave DNA damage response therapies. CAPItello-292: a phase 1b/3 study of capivasertib, palbociclib and fulvestrant versus placebo, palbociclib and fulvestrant in HR+/HER2-advanced breast cancer. DNA damage response. Abstract #1165P. Hamilton, E.

Trials 52

Trials Medicine Antibody Clinical Trials 52

Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Drugs 110

Drugs Licensing Licensing Production 110

Pfizer

NOVEMBER 23, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. No dosage adjustment is needed in patients with mild renal impairment.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. 5) Lynparza (Olaparib) Lynparza is a PARP inhibitor , meaning it inhibits poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

MAY 9, 2023

During his time at General Electric Corporate, he managed the transition of more than 120 HR processes from 12 different business units into a single shared services centre. Jamaels brings expertise from diverse environments to the challenge of change management at Cerba Research.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Big Data 130